Interesting statistics. It would sure be nice to see the numbers increased substantially and for treatment of many other kinds of conditions.

Mediware enters adult stem cell business with acquisition
Kansas City Business Journal by David Twiddy, Reporter
Date: Wednesday, January 4, 2012

Deal puts Mediware in adult stem cell business

David Twiddy
Reporter - Kansas City Business Journal

Mediware Information Systems Inc. is expanding into the adult stem cell business with the acquisition of most of the assets of Transtem LLC.
Lenexa-based Mediware (Nasdaq: MEDW), which already sells software for health care organizations to manage their blood donations and supplies, announced the purchase Wednesday.

Financial details were not released.

St. Louis-based Transtem creates software for managing the collection and transplantation of adult stem cells for cellular therapy and medical research.

In a release, Mediware CEO Thomas Mann said doctors around the world in 2009 used adult stem cells in more than 60,000 transplantations to treat cancer and certain blood diseases. There are 3,600 stem cell clinical trials ongoing.

“Managing the collection, processing and therapeutic use of multiple fractions of adult stem cells is a highly complex process, but it is also a natural extension of Mediware’s core blood management focus, where we have deep clinical and regulatory expertise,” Mann said. “It’s also an area where our existing customers in the U.S. and abroad have expressed a desire for additional support. By acquiring Transtem’s products and expertise, we have the opportunity to take a leadership role in an emerging area of health care, as well as bring innovative new capabilities to our large base of hospitals, academic research centers and specialty outpatient providers.”

The technology also could be extended to others using stem cells and similar substances, including cord blood banks, cell therapy labs, transplant centers and research facilities, the company said.

In November, Mediware reported surging first-quarter profits because of demand for its blood supply management products.